No difference in rate of adverse cardiovascular events when comparing anticoagulants


In patients undergoing transradial primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI), according to a study published in JACC: Cardiovascular Interventions, there is no significant difference in the rate of a composite of death, myocardial infarction and stroke whether they received anticoagulation with bivalirudin or unfractioned heparin

Using data from the National Cardiovascular Data Registry CathPCI Registry, Ion S Jovin (Cardiac Catheterization Laboratories, McGuire Veterans Affairs Medical Center/and associate professor of medicine at Virginia Commonwealth University) and colleagues examined the records of 67,368 patients from 1,584 sites between 2009 and 2015 with STEMI who underwent primary PCI via radial access. Of these patients, 29,660 received bivalirudin and 37,708 received heparin.

Jovin et al adjusted for multiple variables, including a propensity score reflecting the probability of receiving bivalirudin to account for patient differences between groups. After these adjustments, the odds ratio of the composite endpoint of death, myocardial infarction or stroke for bivalirudin vs. heparin was not statistically significant (0.95); the odds ratio for acute stent thrombosis was 2.11 for bivalirudin versus heparin. Major bleeding rates were not significantly different.

According to Jovin, the study’s results are consistent with data from contemporary studies of patients with acute coronary syndrome and STEMI. “Our sensitivity analysis provides some insights into direct comparisons of bivalirudin and heparin when GPIIb/IIIa inhibitors are forced out of the equation and suggests that in the direct comparison bivalirudin may have superior outcomes. However, our study showed that in the real world over a third of the patients with STEMI undergoing transradial PCI who receive heparin and about a fifth of patients who receive bivalirudin also receive GPIIb/IIIa inhibitors.”

The authors suggest that a randomised trial in patients treated exclusively via transradial primary PCI and anticoagulated with bivalirudin versus heparin as well as a cost-effectiveness analysis comparing heparin vs. bivalirudin would help practitioners and hospitals make better decisions regarding anticoagulation in these patients.